ANTI-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY

ABSTRACT

Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, *in vivo* half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.

[FIG. 1A]